

AD\_\_\_\_\_

Award Number: DAMD17-02-1-0270

TITLE: Inducible Anti-Angiogenic Gene Therapy

PRINCIPAL INVESTIGATOR: Paul J. Higgins, Ph.D.

CONTRACTING ORGANIZATION: Albany Medical College  
Albany, New York 12208

REPORT DATE: May 2004

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**BEST AVAILABLE COPY**

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

<b>1. AGENCY USE ONLY</b> (Leave blank)		<b>2. REPORT DATE</b> May 2004	<b>3. REPORT TYPE AND DATES COVERED</b> Annual (15 Apr 2003 - 14 Apr 2004)	
<b>4. TITLE AND SUBTITLE</b> Inducible Anti-Angiogenic Gene Therapy			<b>5. FUNDING NUMBERS</b> DAMD17-02-1-0270	
<b>6. AUTHOR(S)</b> Paul J. Higgins, Ph.D.				
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> Albany Medical College Albany, New York 12208  <i>E-Mail:</i> higginp@mail.amc.edu			<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b>	
<b>9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			<b>10. SPONSORING / MONITORING AGENCY REPORT NUMBER</b>	
<b>11. SUPPLEMENTARY NOTES</b>				
<b>12a. DISTRIBUTION / AVAILABILITY STATEMENT</b> Approved for Public Release; Distribution Unlimited			<b>12b. DISTRIBUTION CODE</b>	
<b>13. ABSTRACT (Maximum 200 Words)</b> Clinical studies have indicated that high breast tumor levels of plasminogen activator inhibitor-1 (PAI-1; SERPINE1) are associated with an increased risk for metastasis, decreased patient survival, tumor angiogenesis and overall poor prognosis. Since PAI-1 is required for both the initiation of tumor-dependent angiogenesis and inhibition of capillary regression, a targeted molecular genetic approach was utilized to ablate PAI-1 synthesis in endothelial cells using antisense PAI-1 constructs and dominant-negative approaches. Such targeting provided proof-of-principle that reduced PAI-1 synthesis and inhibited capillary network formation by immortalized endothelial cells. Adaptation of this methodology to primary endothelial cells provided a means to "tag" cells with a PAI-1-GFP chimeric protein and confirmed that such engineered cells were capable of being incorporated into a hybrid capillary network in vitro. Importantly, use of a dominant-negative version of USF-1, a HLH-LZ transcription factor important in PAI-1 gene control, also attenuated PAI-1 expression in response to growth factor stimulation. Collectively, these results suggest that combinational approaches (PAI-1 antisense/dominant-negative USF-1) may form the basis for more efficient breast cancer anti-angiogenic gene therapy.				
<b>14. SUBJECT TERMS</b> PAI-1, gene therapy, angiogenesis, USF-1, endothelial targeting			<b>15. NUMBER OF PAGES</b> 11	
			<b>16. PRICE CODE</b>	
<b>17. SECURITY CLASSIFICATION OF REPORT</b> Unclassified	<b>18. SECURITY CLASSIFICATION OF THIS PAGE</b> Unclassified	<b>19. SECURITY CLASSIFICATION OF ABSTRACT</b> Unclassified	<b>20. LIMITATION OF ABSTRACT</b> Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)  
Prescribed by ANSI Std. Z39-18  
298-102

20041028 127

## Table of Contents

Cover.....	1
SF 298.....	2
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	7
Reportable Outcomes.....	8
Conclusions.....	8
References.....	9
Appendices.....	1

## Introduction

High tumor levels of plasminogen activator inhibitor type-1 (PAI-1; Serpine1) are consistently associated with an increased risk for metastasis, significantly decreased patient survival and an overall poor prognosis (1,2). The role of PAI-1 as a determinant in tumor progression is particularly relevant in the case of breast cancer where elevated PAI-1 expression in the primary breast carcinoma signals an aggressive angiogenic response (3-10). Tumor-initiated angiogenesis requires proteolysis of the endothelial basement membrane, migration of endothelial cells through the extracellular matrix (ECM) toward the angiogenic stimulus and continued endothelial proliferation behind the migrating front (11-13). Stimulated endothelial cell locomotion requires cycles of ECM adhesion-deadhesion and precise control of the pericellular proteolytic environment (12-14). PAI-1 functions in this process to limit plasmin generation by inhibiting the catalytic activity of urokinase plasminogen activator (uPA) (15,16) modulating, thereby, uPA-dependent ECM degradation and *in vivo* cell motility (17-19). While endothelial cell migration and capillary sprouting requires proteolysis (12,20,21), excessive protease activity prevents the coordinated assembly of endothelial cells into capillary structures highlighting the requirement for an appropriate proteolytic "balance" for a successful angiogenic response (22,23). Genetic studies *in vivo*, moreover, have implicated PAI-1 as an important regulator of this balance (24,25). Indeed, PAI-1 is expressed specifically in angiogenic "cords" and migrating endothelial cells as well as in stromal cells in direct contact with the sprouting neovessels but not in the quiescent endothelium (26-28). Most significantly, PAI-1<sup>-/-</sup> mice are incapable of mounting an angiogenic response either to transplanted tumors or implants of potent angiogenic growth factors (24,27,29); both tumor-associated angiogenesis and tumor invasiveness were restored by injection of PAI-1 expressing adenovirus (24,27). PAI-1 appears to promote angiogenesis specifically by inhibition of plasmin proteolysis, thus preserving an appropriate matrix scaffold for endothelial invasion as well as providing critical stability to the primitive tumor neovessels (18,24,27). Indeed, recent studies have shown that uPA-mediated plasmin generation activates MMP1 and 9 resulting in capillary regression (30). Inhibition of PAI-1 activity with neutralizing antibodies accelerates, whereas exogenous PAI-1 inhibits, capillary regression indicating that endogenous PAI-1 is the major negative regulator of this process (30). Continued PAI-1 expression by the formed capillary structures is required to maintain their stability and, in fact, to prevent regression. Our use of inducible vectors to disrupt PAI-1 synthesis, even in formed capillary structures, will be one novel approach to address the important question of whether PAI-1 targeting can have a therapeutic benefit on existing angiogenic networks. This is an important issue for the treatment of established primary tumors and their developed distant metastases.

## Body of Report

Our work has focused on defining molecular controls on PAI-1 gene expression in normal and transformed cells and clarifying the role of the PAI-1 protein on cellular growth and invasive behavior. We have shown that it is possible to genetically manipulate PAI-1 synthesis in endothelial cells transfected with sense and antisense PAI-1 expression vectors (32,33). We hypothesize, based on our own preliminary and published data, as well as on work done by others (summarized in **Introduction**), that molecular targeting of PAI-1 expression can disrupt both the initial as well as the developed angiogenic response to tumor-derived stimuli. We have recently published a review article that details our in vitro data in support of this contention (Kutz and Higgins, 2004; appended). We propose that targeted attenuation of PAI-1 expression in the developing neovasculature that develops following implantation of human breast carcinoma cells into immunodeficient mice will inhibit the angiogenic response and limit subsequent tumor growth. We further suggest that human endothelial cells genetically-engineered to express inducible PAI-1 antisense transcripts may "home" to sites of active tumor-initiated angiogenesis, incorporate into the developing capillary network, and destabilize the tumor vasculature upon inducible ablation of PAI-1 synthesis. We expect that such engineered cells will ultimately serve as a therapeutic resource for inducible anti-angiogenic therapy of human breast cancer.

To achieve these aims, the goals in Task 2 in the originally proposed **Statement of Work** were addressed in year 02 of this study.

- Task 2.** To assess the ability of infused genetically-engineered human endothelial cells, inducible for expression of PAI-1 antisense transcripts, to incorporate into the developing human breast tumor vasculature and disrupt the supporting capillary network.
- a. Establish that infused green fluorescent protein-"tagged" human endothelial cells are incorporated into the developing angiogenic network.
  - b. Assess the ability of induced PAI-1 antisense transcript expression in vasculature-incorporated human endothelial cells to disrupt tumor-associated capillary vessels and inhibit tumor growth.


Based on the data summarized in the **Introduction**, our working hypothesis is that genetically-induced temporal changes in the expression of PAI-1 may influence endothelial cell migration, capillary formation and/or capillary network stability. Effort in year 02 of this study was devoted to confirmation that the genetic constructs (PAI-1 antisense expression vectors) developed would, in fact, result in attenuated PAI-1 synthesis when transfected into human

endothelial cells (both primary cultures of human endothelial cells as well as the established HMEC-1 line of human microvessel endothelial cells). Transfection studies established that our selected rat PAI-1 mRNA coding sequence, when cloned in antisense orientation into CMV promoter-driven constructs (i.e., in the Rc/CMV expression vector backbone), effectively attenuated PAI-1 synthesis in both mouse (MS1) and rat (T2) endothelial cells (detailed in year 01 Progress Report). We have established (in immortalized rat cells) that genetically-targeted down-regulation of PAI-1 synthesis can inhibit in vitro tubulogenesis likely through the combined action of "scaffold" instability and vessel regression (described in appended paper by Kutz and Higgins, 2004). Rc/CMV plasmid vectors that drive expression of a full-length PAI-1 cDNA insert, cloned in antisense (IAP) orientations, were constructed to be under control of a CMV promoter. To assess the success of Rc/CMVIAP driven down-regulation of PAI-1 synthesis and matrix accumulation, saponin-extracts of <sup>35</sup>S-methionine-labeled cells were separated by gel electrophoresis and proteins visualized by fluorography. One derivative (4HH) did not express detectable PAI-1 protein nor accumulate PAI-1 in the matrix. Wild-type T2 cells formed highly-branched and anastomizing capillary networks when suspended in a complex support matrix consisting of a 3:1 mixture of Vitrogen-Matrigel. Many of these tubular processes had clearly evident lumens. Extensive sprout formation was evident at the tips of T2 branches, moreover, indicative of both invasive and differentiated compartments. PAI-1<sup>-/-</sup> 4HH cells, in contrast, failed to construct stable tubular structures and extensively degraded the gel matrix. Thus, at least within the setting of immortalized rodent endothelial lines, our targeting strategy (i.e., delivery of constitutively-expressing PAI-1 antisense constructs) has the expected outcome on gene expression and the tubulogenic phenotype.

To address specifically the issue that genetically-engineered human endothelial cells are capable of incorporation into a developing angiogenic network, the pEGFP-1 vector in which the GFP insert was expressed as a fusion protein with PAI-1 and driven by PAI-1 promoter sequences was used (Kutz and Higgins, 2004; appended). Human microvessel endothelial cells (HMEC-1) were transfected with pEGFP-1 and the ability of these cells to incorporate into a tubulogenic network confirmed by co-culture with T2 cells on Matrigel-coated surfaces. Once proof-of-principle was established, primary cultures of mouse endothelial cells were prepared to confirm that "normal" (i.e., non-immortalized) cells could be similarly "tagged" and incorporate into hybrid vessels (a paper describing both preparation of engineered endothelial cells and their ability to produce chimeric capillary networks is in preparation and will be forwarded to USAMRMC upon acceptance for publication).

We are currently testing tet-inducible PAI-1 antisense constructs in both human (HMEC-1) and primary mouse endothelial cells to determine if expression induction will produce network instability results similar to those induced by the constitutively-expressed Rc/CMVIAP vector in immortalized cells (described in Kutz and Higgins, 2004; appended).

We have also determined that a major transcriptional regulator of PAI-1 expression is the transcription factor USF-1. When expressed as a dominant-negative construct (USF-1A), this factor markedly suppresses PAI-1 transcription. We are currently investigating the possibility that PAI-1 antisense and USF-1 expression vectors will be therapeutically useful as a combinational anti-angiogenic strategy.



**Figure 1. Dominant-negative USF-1 (USF-1A) attenuates TGF-β1-induced PAI-1 protein expression and barrier invasion.** USF-1 was confirmed to be an endogenous PAI-1 promoter PE2 region DNA-binding factor by chromatin immunoprecipitation using antibodies to USF-1 (A). Controls included addition of sonicated cellular DNA but without immunoprecipitation (input DNA), addition of PAI-1p806-Luc DNA as a control template for PCR (template DNA) and PCR reaction mixtures with H<sub>2</sub>O in place of DNA (-DNA). L = sizing ladder. To evaluate the effects of molecular genetic interference with USF function, RK cells were untransfected or transfected with CMV-driven WT USF-1 or CMV-driven dominant-negative USF-1A. Whole cell lysates from quiescent cultures or cells stimulated with 20% FBS or 1 ng/ml TGF-β1 were collected, separated on 9% SDS-PAGE, proteins transferred, and blots probed with anti-rat PAI-1 antibody (B). Transfers were reprobed with antibodies to ERK1/2 to assess protein loading. Invasion of RK cells expressing either WT (USF-1) or dominant-negative (USF-1A) expression constructs was compared ± TGF-β1 (C). Data in (C) specifically represent TGF-β1-induced fold-invasion of Matrigel-coated barriers (i.e., TGF-β1-associated invasion/untreated controls); histogram represents mean±standard error from 8 migration evaluations.

## Key Research Accomplishments

It was confirmed (in immortalized cells) that genetic targeting of PAI-1 transcripts resulted in attenuation of PAI-1 synthesis and inhibition of capillary network formation.

Human (HMEC-1) and primary mouse endothelial cells were successfully "tagged" with an expression vector encoding a chimeric PAI-1 green fluorescent protein marker driven by PAI-1 promoter sequences.

"Tagged" endothelial cells were capable of producing hybrid capillary networks when co-cultured with tubulogenic T2 cells on Matrigel-coated surfaces.



PAI-1 gene expression was positively regulated by upstream stimulatory factor-1 (USF-1), a member of the helix-loop-helix-leucine zipper transcription factor family. Use of a dominant-negative USF-1 construct effectively attenuated growth factor-induced PAI-1 expression. These findings suggest that combinational approaches using antisense PAI-1 and dominant-negative USF-1 constructs may form the basis for more efficient anti-angiogenic gene therapy.

Tet-inducible constructs are presently under development.

### **Reportable Outcomes**

All genetically-engineered immortalized (HMEC-1, T2) cells will be maintained in the laboratory of the PI. The pEGFP-1 and dominant-negative USF-1A plasmids are also stored as frozen stocks in the laboratory. Tet-inducible systems are currently being developed in human breast cancer cell lines (MCF-7), human epithelial cells (HaCaT) and in the T2 + HMEC-1 cells as well as primary endothelial cells. These resources will be made available upon request to members of the scientific community engaged in breast cancer research. Dr. Stacie Kutz has devoted 30% of her time/effort to this project during the report period. She is largely responsible for PAI-1 gene control studies in T2 cells including development of USF-1 controls on PAI-1 expression. Qunhiu Ye has replaced Jianzhong Tang on this project.

### **Conclusions**

The present work is based largely on our continuing hypothesis that molecular targeting of PAI-1 expression in angiogenic vessels represents a unique gene therapy approach that has the distinct advantages of (1) potential cell-specific construct targeting and (2) a high likelihood of success when directed to established angiogenic "beds". Our laboratory has had considerable experience in the construction and utilization of both sense and antisense PAI-1 expression vectors (summarized in the **Introduction**), and more recently, in the design of small molecule inhibitors of PAI-1 function and PAI-1 gene expression in endothelial cells incorporated into formed capillary structures, constitutes an important approach to address the critical question of whether PAI-1 targeting can have a therapeutic benefit on existing angiogenic networks. We envision that a multifaceted attempt to target PAI-1 gene expression in both breast carcinoma cells (see **Introduction**) and in the collateral tumor vascular network would likely require cell type-specific expression modulation control. The goals described in this funded program, in conjunction with the general scope of work ongoing in the laboratory of the PI, reflect these separate but focused efforts to utilize gene therapy approaches to maximize a positive outcome for the management of human breast cancer.



## References

1. Duffy, M.J. (1996) Proteases as prognostic markers. *Clin. Cancer Res.* 2, 613-618.
2. Eppenberger, U., Kueng, W., Schaeppi, J.M., Roesel, J.J., Benz, C., Mueller, H., Matter, A., Zuber, M., Leuscher, K., Litschgi, M., Schmitt, M., Koekens, J.A., Eppenberger-Castori, S. (1998) Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subjects of node-negative breast cancer patients. *J. Clin. Oncol.* 19, 3129-3136.
3. Constantini, V., Sidoni, A., Devegilia, R., Cazzato, O.A., Bellezza, G., Ferri, I., Bucciarelli, E., Nenci, G.G. (1996) Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. *Cancer* 77, 1079-1088.
4. Gandolfo, G.M., Conti, L., Vercillo, M. (1996) Fibrinolysis components as prognostic markers in breast cancer and colorectal carcinoma. *Anticancer Res.* 16, 2155-2159.
5. Mayerhofer, K., Stolzlechner, J., Yildiz, S., Haider, K., Heinzl, H., Jakesz, R., Pecherstorfer, M., Rosen, H., Sevela, P., Zeillinger, R., Speiser, P. (1996) Plasminogen activator inhibitor 1 and prognosis in breast carcinoma. *Geburt, Frauenheil.* 56, 23-27.
6. Fersis, N., Kaufmann, M., Karner, M., Wittmann, G., Wallwiener, D., Basert, G. (1996) Prognostic significance of plasminogen activator inhibitor-1 in primary breast carcinoma. *Geburt, Frauenheil.* 56, 28-34.
7. Torre, E.A., Fulco, R.A. (1996) Tumor-associated urokinase plasminogen activator: significance in breast cancer. *Europ. J. Gynaecol. Oncol.* 17, 315-318.
8. Foekens, J.A., Look, M.P., Peters, H.A., van Putten, W.L., Portengen, H., Klijn, J.G. (1995) Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. *J. Natl. Cancer Inst.* 87, 751-756.
9. Hildebrand, R. (1995) Novel methods for the determination of the angiogenic activity of human tumors. *Breast Cancer Res. Treat.* 36, 181-192.
10. Tonnesen, M.G., Feng, X., Clark, R.A. (2000) Angiogenesis in wound healing. *J. Invest. Derm. Symp. Proc.* 5, 40-46.
11. Iwasaka, C., Tanaka, K., Abe, M., Sato, Y. (1996) Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. *J. Cell. Physiol.* 169, 522-531.
12. Madri, J.A., Sankar, S., Romanic, A.M. (1996) Angiogenesis. In: *The Molecular and Cellular Biology of Wound Repair* (Clark, R.A.F., editor), Plenum Press, N. 355-371.
13. Greenwood, J.A., Murphy-Ullrich, J.E. (1998) Signaling of de-adhesion in cellular regulation and motility. *Microsc. Res. Tech.* 43, 420-432.

14. Mignatti, P., Rifkin, D.B., Welgus, H.G., Parks, W.C. (1996) Proteinases and tissue remodeling. In: *The Molecular and Cellular Biology of Wound Repair* (Clark, R.A.F., editor), Plenum Press, NY, 427-474.
15. Pollanen, J., Ross, W., Vaheri, A. (1991) Directed plasminogen activation at the surface of normal and transformed cells. *Adv. Cancer Res.* 57, 273-328.
16. Hiraoka, N., Allen, E., Apel, I.J., Gyetee, M.R., Weiss, S.J. (1998) Matrix metalloproteinases regulates neovascularization by acting as pericellular fibrinolysis. *Cell* 95, 365-377.
17. Cajot, J.F., Bamat, J., Bergonzelli, G.E., Kruithof, E.K., Medcalf, R.L., Testuz, J. and Sordat, B. (1990) Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. *Proc. Natl. Acad. Sci. USA* 87, 6939-6943.
18. Mignatti, P. and Rifkin, D.B. (2000) Nonenzymatic interactions between proteinases and the cell surface: novel roles in normal and malignant cell physiology. *Adv. Cancer Res.* 78, 103-157.
19. Carmeliet, P., Collen, D. (1998) Gene targeting and gene transfer studies of the plasminogen/plasmin system: implications in thrombosis, hemostasis, enointimia formation, atherosclerosis. *FASEB J* 9, 934-938.
20. Mandriota, S.J., Pepper, M.S. (1997) Vascular endothelial growth factor-induced in vitro angiogenesis and plasminogen activator expression are dependent on endogenous basic fibroblast growth factors. *J. Cell Sci.* 110, 2293-2302.
21. Montesano, R., Pepper, M.S., Vassalli, J.D., Orci, L. (1987) Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors. *J. Cell Physiol.* 132, 509-516.
22. Pepper, M.S., Belin, D., Montesano, R., Orci, L., Vassalli, J.D. (1990) Transforming growth factor- $\beta$ 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cells in vitro. *J. Cell Biol.* 111, 743-755.
23. Lambert, V., Munaut, C., Noel, A., Frankenhe, F., Bajou, K., Gerard, R., Carmeliet, P., Defresne, M.P., Foidart, J.M., Rakic, J.M. (2001) Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. *FASEB J* 15, 1021-1027.
24. Bajou, K., Masson, V., Gerard, R.D., Schmitt, P.M., Albert, V., Praus, M., Lund, L.R., Frandsen, T.C., Brunner, N., Dano, K., Fusenig, N.E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J.M., Noel, A. (2001) The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin: implications for antiangiogenic strategies. *J. Cell Biol.* 152, 777-784.
25. Pepper, M.S., Sappino, A.P., Montesano, R., Orci, L., Vassalli, J.D. (1992) Plasminogen activator inhibitor-1 is induced in migrating endothelial cells. *J. Cell Physiol.* 153, 129-139.
26. Bacharach, E., Itin, A., Keshet, E. (1998) Apposition-dependent induction of plasminogen activator inhibitor type 1 expression: a mechanism for balancing pericellular proteolysis during angiogenesis. *Blood* 92, 939-945.

27. Bajou, K., Noel, A., Gerard, R.D., ;Masson, V., Brunner, N., Holst-Hansen, C., Skobe, M., Fusenig, N.E., Carmeliet, P., Collen, D., Foidart, J.M. (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. *Nature Med* 4, 923-928.
28. Lane, T.F., Iruela-Arispe, M.L., Sage, E.H. (1992) Regulation of gene expression by SPARC during angiogenesis in vitro. Changes in fibronectin, thrombospondin-1, and plasminogen activator inhibitor-1. *J. Biol. Chem.* 267, 16736-16745.
29. Gutierrez, L.S., Schulman, A., Brito-Robinson, T., Noria, F., Ploplis, V.A., Castellino, F.J. (2000) Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. *Cancer Res.* 60, 5839-5847.
30. Davis, G.E., Allen, K.A.P., Salazar, R., Maxwell, S.A. (2001) Matrix metalloproteinase-1 and -9 activation by plasmin regulates a novel endothelial cell-mediated mechanism of collagen gel contraction and capillary tube regression in three-dimensional collagen matrices. *J. Cell Sci.* 114, 917-930.
31. Seebacher, T., Manske, M., Zoller, J., Crabb, J., Blade, E.G. (1992) The EGF-inducible protein EIP-1 of migrating normal and malignant rat liver epithelial cells is identical to plasminogen activator inhibitor 1 and is a component of the ECM migration tracks. *Exp. Cell Res.* 203, 504-507.
32. Providence, K.M., Kutz, S.M., Staiano-Coico, L., and Higgins, P.J. (2000) PAI-1 gene expression is regionally induced in wounded epithelial cell monolayers and required for injury repair. *J. Cell Physiol.* 182, 269-280.
33. Kutz, S.M., Providence, K.M., Higgins, P.J. (2001) Antisense targeting of c-fos transcripts inhibits serum- and TGF- $\beta$ 1 stimulated PAI-1 gene expression and directed motility in renal epithelial cells. *Cell Motil. Cytoskeleton* 48, 163-174.